MORIFA

Morifa is a biotechnology company specializing in the development and manufacture of recombinant humanized collagen and other high-performance biomaterials. Utilizing a proprietary synthetic biology platform, the company focuses on creating biocompatible proteins for applications in medical aesthetics, wound repair, and regenerative medicine. Morifa's lead products include recombinant humanized collagen type III, which is designed to mimic natural human collagen for improved safety and efficacy in skin rejuvenation and tissue engineering. The company aims to replace animal-derived collagen with sustainable, high-purity recombinant alternatives. Morifa is currently expanding its portfolio to include various types of humanized collagen and other bioactive proteins for the global healthcare market.